Document is current
Any future updates will be listed below
-
Authors
Vulin, Milica http://orcid.org/0000-0002-7686-5102
Jehanno, Charly
Sethi, Atul
Correia, Ana Luísa
Obradović, Milan M. S.
Couto, Joana Pinto
Coissieux, Marie-May
Diepenbruck, Maren
Preca, Bogdan-Tiberius
Volkmann, Katrin
der Maur, Priska Auf http://orcid.org/0000-0002-9059-8979
Schmidt, Alexander http://orcid.org/0000-0002-3149-2381
Münst, Simone
Sauteur, Loïc http://orcid.org/0000-0002-9163-0424
Kloc, Michal http://orcid.org/0000-0002-4575-7723
Palafox, Marta
Britschgi, Adrian
Unterreiner, Vincent
Galuba, Olaf
Claerr, Isabelle
Lopez-Romero, Sandra
Galli, Giorgio G. http://orcid.org/0000-0002-9401-060X
Baeschlin, Daniel
Okamoto, Ryoko
Soysal, Savas D.
Mechera, Robert
Weber, Walter P.
Radimerski, Thomas
Bentires-Alj, Mohamed http://orcid.org/0000-0001-6344-1127
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Novartis
Krebsliga Beider Basel
- License Information
-
More Information
Article History
Received: 4 January 2022
Revised: 25 July 2022
Accepted: 26 July 2022
First Online: 25 August 2022
Competing interests
: MV, CJ, ALC, PAdM, TBP, MD, ASc, M-MC, KV, LS, RO, SDS, RM, declare no competing financial interests. AB, ASe. and MMSO are employees of F. Hoffmann–La Roche. JPC, VU, OG, IC, SL-R, GG, and DB are employees of Novartis. TR is an employee of Basilea. SM is part of a digital advisory board for Roche. WPW received research support from Takeda Pharmaceuticals International paid to the Swiss Group for Clinical Cancer Research (SAKK) and personal honoraria from Genomic Health. Support for meetings was paid to his institution from Sandoz, Genomic Health, Medtronic, Novartis Oncology, Pfizer and Eli Lilly. MB-A owns equities in and has received laboratory support and compensation from Novartis, and serves as a consultant for Basilea.
